Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant. Academic Article uri icon

Overview

publication date

  • March 26, 2021

Research

keywords

  • Antineoplastic Agents
  • Drug Resistance, Neoplasm
  • Glycine
  • Hematopoietic Stem Cell Transplantation
  • Isocitrate Dehydrogenase
  • Leukemia, Myeloid, Acute
  • Mutation
  • Neoplasm Recurrence, Local
  • Pyridines

Identity

Scopus Document Identifier

  • 85103135624

Digital Object Identifier (DOI)

  • 10.1038/s41375-021-01229-x

PubMed ID

  • 33772143

Additional Document Info